<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136474</url>
  </required_header>
  <id_info>
    <org_study_id>02-292</org_study_id>
    <nct_id>NCT00136474</nct_id>
  </id_info>
  <brief_title>Amifostine for Head and Neck Irradiation in Lymphoma</brief_title>
  <official_title>A Randomized Phase II Trial of Amifostine for Head and Neck Irradiation in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine the effects (good and bad) amifostine has on
      radiation-induced side effects of lymphoma treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into one of two study groups. One study group will receive
      amifostine prior to daily radiation therapy and the other group will receive radiation
      therapy alone.

      Amifostine will be administered 30-60 minutes prior to radiation treatment. Vital signs will
      be monitored 5 minutes and 15 minutes after amifostine injection as well as immediately
      following radiation treatment.

      Patients will also complete a quality-of-life questionnaire on the first and last day of
      radiation treatment. Follow-up questionnaires will be done at follow-up visits 1 month, 3
      months, 6 months, 12 months, 18 months and 24 months after completion of radiation therapy.

      Patients will be removed from the study if they develop an allergic reaction to amifostine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effectiveness of amifostine in reducing acute and chronic radiation-induced side effects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the quality-of-life of patients receiving radiation therapy and amifostine</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the safety of amifostine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amifostine plus radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>Given 30-60 minutes prior to daily radiation therapy</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Daily radiation therapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be 35 years or older

          -  Histologically confirmed Hodgkin's disease or non-Hodgkin's lymphoma receiving
             radiation therapy to the head and neck area.

          -  Involvement of one or more of the following sites: cervical node, supraclavicular
             node, pre-auricular node, submental node, any salivary glands, any parts of the oral
             cavity, or any parts of the oropharynx.

        Exclusion Criteria:

          -  Prior history of head and neck malignancies

          -  Prior radiation therapy to the head and neck region

          -  Patients with stage I Hodgkin's disease receiving radiation therapy alone

          -  Pregnant or lactating women

          -  Myocardial infarction within the 6 months of enrollment

          -  Clinically evident pulmonary insufficiency, except for patients with exertional
             dyspnea related to chest tumor itself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea K. Ng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>October 30, 2009</last_update_submitted>
  <last_update_submitted_qc>October 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Andrea K. Ng, MD</name_title>
    <organization>Dana-Farber Cancer Institute/Brigham and Women's Hospital</organization>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Amifostine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

